SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
SEC Accession No. 0001193125-24-032176
Filing Date
2024-02-12
Accepted
2024-02-12 16:36:25
Documents
2
Group Members
ABINGWORTH BIOVENTURES 8 LPABINGWORTH BIOVENTURES VII LPABINGWORTH LLPCARLYLE GENESIS UK LLCCARLYLE HOLDINGS I GP INC.CARLYLE HOLDINGS I GP SUB L.L.C.CARLYLE HOLDINGS I L.P.CARLYLE INVESTMENT MANAGEMENT L.L.C.CG SUBSIDIARY HOLDINGS L.L.C.TC GROUP, L.L.C.

Document Format Files

Seq Description Document Type Size
1 SC 13G/A d766962dsc13ga.htm SC 13G/A 188431
2 EX-24 d766962dex24.htm EX-24 11784
  Complete submission text file 0001193125-24-032176.txt   202464
Mailing Address C/O THE CARLYLE GROUP 1001 PENNSYLVANIA AVENUE, N.W. WASHINGTON DC 20004
Business Address C/O THE CARLYLE GROUP 1001 PENNSYLVANIA AVENUE, N.W. WASHINGTON DC 20004 202 729 5626
Carlyle Group Inc. (Filed by) CIK: 0001527166 (see all company filings)

IRS No.: 452832612 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A
SIC: 6282 Investment Advice
(CF Office: 02 Finance)

Mailing Address 100 CAMPUS DRIVE, SUITE 102 FLORHAM PARK NJ 07932
Business Address 100 CAMPUS DRIVE, SUITE 102 FLORHAM PARK NJ 07932 (877) 742-8466
Phathom Pharmaceuticals, Inc. (Subject) CIK: 0001783183 (see all company filings)

IRS No.: 824151574 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-91182 | Film No.: 24620604
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)